Bristol Myers Onureg Scores European Approval As Maintenance Therapy For Acute Myeloid Leukemia

by Vandana Singh, Benzinga Editor

June 18, 2021 1:25 PM | 1 min read |

The European Commission has granted full marketing authorization to Bristol Myers Squibb & Co's BMY Onureg (azacitidine tablets)
The approval comes as maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission or complete remission with incomplete blood count recovery after induction therapy with or without consolidation treatment and who are not candidates for hematopoietic stem cell transplantation.
Onureg is approved in the U.S. for the same set of AML patients.
Price Action: BMY shares are down 0.48% at $66.45 during the market trading session on the last check Friday.

Posted In: Biotech News Health Care FDA General acute myeloid leuxemia Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.